Fundraising FoxAlexandria
Corporate VCPasadena · Seed–Late Stage · 29 people tracked
Also known as Alexandria Venture Investments
Find your way into Alexandria
Each arrow is one introduction. Sign up to fill in the first one.
Ask Dave Barrett to introduce you to Hallie E. Kuhn
You →Dave · together at Polaris Partners →Hallie
Ask Jamie Chen to introduce you to Jenna Foger
You →Jamie · together at Easton Associates (acquired by Navigant Consulting, Inc.) →Jenna
Ask Sam Okafor to introduce you to Don Rose
You →Sam · together at Hatteras Venture Partners →Don
- Peter M. Moglia116 people can intro you
- Joel S. Marcus8 people can intro you
Sign up to find every way you can get introduced to Alexandria
- Your email: who you already know at Alexandria, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Alexandria team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Investment thesis
Alexandria operates a strategic venture capital platform, Alexandria Venture Investments, launched in 1996 as part of the broader REIT's mission to advance human health. The platform actively invests in disruptive life science companies developing transformative new modalities, platforms, and innovative medicines. Investment activity is integrated with the company's life science real estate ecosystems and innovation clusters across key North American markets including Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle, and New York City. The firm also pursues a national agtech investment strategy and emphasizes catalyzing life-changing innovation that benefits human health and society.
Source: firm website, verified Oct 2, 2026.
Team · 29 people
from the firm's website & curated & public directoriesFounder mafia
2 people who came through Alexandria went on to found or lead other companies.
What they invest in
from 101 of 116 portfolio companiesBiotech ×86Healthtech ×40Deep Tech ×24AI & Machine Learning ×23Medical Devices ×20Digital Health ×6Enterprise Software ×4AgTech ×3
HQs:United States×91Australia×1Canada×1Norway×1
Investments · 116 tracked
founders shown can be your intro pathBy year:2026 · 52025 · 72024 · 92023 · 62022 · 102021 · 132020 · 72019 · 102018 · 112017 · 82016 · 32015 · 292 dated
Boundless Bio develops precision oncology medicines targeting ecDNA-amplified cancers, specifically creating a new category of ecDNA-directed therapies for patients with oncogenic alterations.
BiotechMedical DevicesLa Jolla, US
Zachary D. Hornby(Executive Officer, Director)inRobert Doebele(Chief Medical Officer)inChristian Hassig(Chief Scientific Officer)Jessica Oien(Chief Legal Officer and Corporate Secretary)in
BoardBenjamin Cravatt, Ph.D.(Director)Kristina Burow(Director)in
Co-investorsARCH Venture PartnersNextech InvestRA CapitalCity Hill VenturesNEXTECH ONCOLOGY SCSPSectoral Asset Management+4 more
Disc Medicine is a biopharmaceutical company developing therapies from discovery through clinical development for patients in need.
BiotechHealthtech
John Quisel(Chief Executive Officer)inJean Franchi(Chief Financial Officer)inJonathan Yu(Chief Operating Officer)inWill Savage(Chief Medical Officer)inPamela Stephenson(Chief Commercial Officer)inSteve Caffé(Chief Regulatory Officer)in
Co-investorsAccess BiotechnologyAtlas VentureBain Capital Life SciencesForesite CapitalFrazier Life SciencesOrbiMed+6 more
Imara is a clinical-stage biopharmaceutical company developing small molecule therapeutics for unmet medical needs, currently advancing ELVN-001, a selective kinase inhibitor designed to treat chronic myeloid leukemia by targeting the BCR-ABL gene fusion.
BiotechCambridge, US
James G. McArthur(Executive Officer, Director)Christoph M. Adams(Executive Officer, Director)Richard Fair(President, Chief Executive Officer, Director)
BoardSara Nayeem(Director)Barbara Dalton(Director)David Mott(Director)
Co-investorsBay City CapitalNew Enterprise Associates (NEA)RA CapitalArix BioscienceLundbeckfonden VenturesOrbiMed+2 more
Korro Bio is a biotechnology company developing a new class of RNA-editing therapies guided by human genetics and disease biology.
BiotechHealthtechCambridge, US
Nessan Bermingham(Mr. Bermingham is the Executive Chair of the Issuer.)inJean-François Formela(Director)inOmmer Chohan(Mr. Chohan is the Secretary and Treasurer of the Issuer.)inRam Aiyar(Chief Executive Officer, President and Director)inTodd Chappell(Chief Operating Officer)in
BoardJean-Francois Formela(Director)in
Co-investorsAtlas VentureMC Healthcare VenturesNew Enterprise Associates (NEA)Qiming Venture Partners USARock Springs CapitalTaiwania Capital+1 more
Maze Therapeutics develops precision medicines for common diseases with high unmet need, using its Compass platform based on human genetics and variant functionalization.
AI & Machine LearningBiotechSouth San Francisco, US
Charles Homcy(Director)Jason Coloma(Chief Executive Officer)in
Co-investorsAndreessen HorowitzARCH Venture PartnersForesite CapitalFrazier Life SciencesGV (Google Ventures)Hercules Capital, Inc.+9 more
Neumora is a clinical research company developing investigational medications, with a focus on conducting clinical trials to obtain regulatory approval and make treatments available to patients.
BiotechDeep TechDigital HealthMedical DevicesWatertown, US
Paul L. Berns(Chairman and Chief Executive Officer)Joshua Pinto(Executive Officer)Tamara Tompkins(Executive Officer)inKari Stefansson(Director)Maykin Ho(Director)Alaa Halawa(Director)
Co-investorsARCH Venture PartnersCatalio Capital Management, LPF-Prime CapitalK2 HealthVenturesMercury FundPremier Partners+10 more
Senti Bio develops cell and gene therapies for cancer and difficult-to-treat diseases using synthetic biology and engineered Gene Circuits to enhance precision, control, and selectivity in targeting tumor cells.
BiotechDeep TechMedical DevicesSouth San Francisco, US
Tim Lu(Co-Founder and Chief Executive Officer)inPhilip Lee(Executive Officer)inKanya Rajangam(President, Head of Research & Development and Chief Medical Officer)inYvonne Li(Executive Officer)inJames Collins(Director)
BoardDonald Tang(Director)
Co-investorsEvolution VC PartnersFlucas VenturesLifeforce CapitalLifeSci Venture PartnersLux CapitalMenlo Ventures+12 more
Congruence is a drug discovery company that applies protein dynamics, biophysics, machine learning, and computational chemistry to model proteins in their full dynamic state and predict disease correction in silico.
AI & Machine LearningBiotechDeep Tech
Clarissa Desjardins(Founder)in
Co-investorsOrbiMedDIMENSIONAngelini VenturesBDC Thrive Venture Fund for WomenLumira VenturesAmplitude Venture Capital+1 more
Thryv Therapeutics is a clinical-stage biotechnology company developing selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK1) for inherited cardiac arrhythmias such as Long QT Syndrome and acquired cardiometabolic diseases.
BiotechHealthtechMedical Devices
Paul F. Truex(Chairman of the Board & Chief Executive Officer)inDebra OdinkinAmy Sehnertin
Co-investorsAmzak HealthadMare BioInnovationsCTI Life Sciences Fund L.P.Lumira Ventures
Applied Therapeutics is a biopharmaceutical company developing novel drugs for rare diseases with high unmet medical need.
BiotechHealthtechNew York, US
Shoshana Shendelman(Executive Officer, Director)in
BoardLes Funtleyder(Director)
Board seatJoel S. Marcus· per SEC Form D · $20M raise · filed Nov 2019
Co-investorsEvolution VC PartnersVenrock Healthcare Capital Partners
Ability is a biotechnology company developing highly-selective, immune cell-modulating antibody therapeutics for patients with inflammatory diseases and cancer.
AI & Machine LearningBiotechHealthtechMontreal, CA
Co-investorsPage One VenturesFonds de solidarité FTQ
Ability.ai builds AI agents that automate repetitive, rule-based workflows across business functions like customer support, HR, marketing, sales, finance, and IT, which customers deploy on their own platform called Trinity.
AI & Machine LearningDeveloper ToolsEnterprise SoftwareSaaSSales TechSan Francisco, US
Eugene Vyborov(Founder and CEO)in
Co-investorsSID Venture Partners1991 VenturesFonds de solidarité FTQ
AeroRx is a clinical-stage biopharmaceutical company developing nebulized fixed-dose combination therapies (LABA/LAMA and triple LABA/LAMA/ICS) for moderate-to-severe COPD patients who are underserved by inhalers.
BiotechHealthtechLa Jolla, US
Ahmet Tutuncu(CEO and Co-founder)inAhmet Tutuncu, M.D., Ph.D.(Executive Officer, Director)
BoardTighe Reardon(Executive Officer)Heather Preston, M.D.(Director)Jay B. Lichter, Ph.D.(Director)Sanford Madigan, Ph.D.(Director)
Co-investorsAvalon BioVenturesCorrelation Ventures
ARTBIO develops alpha radioligand therapies (ARTs) for cancer treatment, designing target-and-molecule combinations intended to kill tumors while sparing healthy tissue.
BiotechHealthtechMedical DevicesOslo, NO
Roy Larsen(Scientific Founder)Øyvind Bruland(Scientific Founder)Margaret Yu(Chief Medical Officer)Philippe Dasse(Chief Technical Officer)Amra Demirovic(Chief Human Resources Officer)Nicole Hadas(Chief Legal Officer)
Co-investorsB Capital GroupB4 CapitalF-Prime CapitalSofinnova VenturesB CapitalOmega Funds+2 more
.jpeg){kind=logo}
Asher Bio develops selective immunotherapy drugs that target specific immune cell types to promote beneficial effects while minimizing toxicity.
BiotechHealthtechMedical DevicesSan Francisco, US
Ivana Djuretic(Founder)inAndy Yeung(Founder)inYik Andy Yeung(Executive Officer, Director, Promoter)
Co-investorsEmles Venture PartnersGoAhead VenturesMission Bay CapitalMission BiocapitalRA CapitalY Combinator+8 more
Aspen Neuroscience develops iPSC-derived autologous cell therapies for neurological diseases, with a lead product (ANPD001) in Phase 1/2a clinical trials for Parkinson's disease.
BiotechDeep TechDigital HealthMedical DevicesSan Diego, US
Andrés Bratt-Leal(Co-Founder and Senior Vice President, Research & Development)inANDRÉS BRATT-LEAL, Ph.D.(Co-Founder; Senior Vice President, Research & Development)Damien McDevitt(President and Chief Executive Officer)inDAMIEN MCDEVITT, Ph.D.(President and Chief Executive Officer)
Co-investorsARCH Venture PartnersLifeforce CapitalOrbiMedDomain AssociatesEDB InvestmentsSection 32+8 more
Clinical-stage drug-device company developing pegloprastide (AVB-620) for real-time surgical margin detection in cancer surgery.
Co-investorsTorrey Pines Investment
Bear Flag Robotics developed autonomous technology for farming before being acquired by John Deere in 2021.
Advanced ManufacturingAgTechRoboticsNew York City, US
Igino Cafiero(Founder/CEO)inAubrey Donnellan(Founder)in
Co-investorsAgFunderExpansion Venture CapitalGraphene VenturesGreen Cow Venture CapitalIndustrious VenturesLiquid Ventures+8 more
.jpeg){kind=logo}
Confluence Genetics (operating at bensonhillbio.com) is a seed innovation company that develops soybean genetics using AI-driven plant science and proprietary tools such as eMERGE Genetics and CropOS.
Durham, US
Matthew B Crisp(Executive Officer, Director)Lee Palles(Executive Officer)inNadine Carozzi(Executive Officer)Todd C Mockler(Executive Officer)Thomas Brutnell(Executive Officer)
BoardDaniel J Broderick(Director)
Co-investorsActivant CapitalFall Line CapitalGV (Google Ventures)iSelect FundLewis & Clark VenturesMercury Fund+3 more
Bright Peak Therapeutics is a biotechnology company developing multi-functional PD-1 inhibitors for cancer immunotherapy, based on its EDC protein-engineering platform.
BiotechHealthtechSan Diego, US
Vijaya Pattabiraman(Co-founder & Chief Technology Officer)inJeffrey Bode(Scientific co-founder; Professor at ETH Zürich)inFredrik Wiklund(Chief Executive Officer)Christine Siu(Director)Michael Rosenzweig(Director)Bertolt Kreft(Executive Officer)
Co-investorsRA CapitalJohnson & Johnson Innovation – JJDCVersant VenturesVenrockBlackRockFidelity Investments+2 more
Combines single-cell RNA analysis technology from the Broad Institute with AI/ML models and large-scale clinical sample collection for novel drug discovery and precision medicine.
HealthtechCambridge, US
Tariq Kassum(Executive Officer, Director)inMichael Boretti(Executive Officer)inChristoph Lengauer(Executive Officer, Director)in
Co-investorsCatalio Capital Management, LPFast Track InitiativeGV (Google Ventures)Casdin CapitalThird Rock Ventures
Cambridge, MA clinical-stage biotech developing engineered exosome therapeutics; IPO'd on NASDAQ in 2020, later restructured.
BiotechSeattle, US
Doug Williams(Executive Officer, Director)in
BoardNoubar Afeyan(Director)inSteven Gillis(Director)Eric Lander(Director)
Co-investorsARCH Venture PartnersEcoR1 CapitalFidelity InvestmentsFlagship PioneeringQatar Investment Authority
Creyon develops cell-specific therapeutics using aptamer-delivered oligonucleotides, engineering aptamers to deliver therapeutic payloads to immune cells and across the blood-brain barrier for immune-driven and CNS diseases, plus a splice-switching oligonucleotide program for late-onset Pompe disease.
AI & Machine LearningBiotechDeep Tech
Co-investorsBioBritDCVC (Data Collective)DCVC BioTenmileCasdin CapitalLux Capital
Delphia Therapeutics is a biotechnology company developing cancer medicines based on its activation lethality platform, aiming to create therapies effective on their own while combating resistance to targeted therapies.
BiotechHealthtechCambridge, US
Kevin Marks(Founder)in
Co-investorsGV (Google Ventures)Nextech InvestTaiho Ventures, LLC
Dewpoint Therapeutics develops condensate-modulating drugs by using an integrated platform that maps, measures, and modulates biomolecular condensates to identify druggable targets and disease mechanisms.
AI & Machine LearningBiotechDeep TechBoston, US
Richard Young, Ph.D.(Director)inAnthony Hyman, Ph.D.(Director)Tony Hyman(Scientific Co-founder)Rick Young(Scientific Co-founder)Elisabeth Leiderman(Executive Officer)inAmeet Nathwani, M.D.(Executive Officer, Director)in
Co-investorsARCH Venture PartnersEcoR1 CapitalSamsara BioCapital6 Dimensions CapitalGeneral CatalystInnovation Endeavors+6 more
.png)
Dispatch Bio develops a universal immunotherapy treatment for solid tumors, combining engineered immunotherapy with a tumor-specific virus to improve cancer treatment outcomes.
BiotechDeep TechMedical Devices
Lex Johnson(Co-Founder and Chief Platform Officer)inRay Liu(Co-founder and Head of Synthetic Biology)Jeff Marrazzo(Founder)inSabah Oney(Chief Executive Officer)in
Co-investorsARCH Venture PartnersStanford University
Dren Bio is a clinical-stage biopharmaceutical company developing novel antibody therapeutics designed to selectively eliminate pathogenic cells and disease-causing agents, with a pipeline targeting oncology, autoimmune diseases, immunology, and neurology.
BiotechHealthtechMedical DevicesFoster City, US
Nenad Tomasevic(Chief Executive Officer, Founder)
BoardIvan Trifunovich(Director)John Wesley(Director)
Co-investors8VCAisling CapitalHBM Healthcare InvestmentsHBM PartnersMission Bay CapitalMission Biocapital+4 more
Dualitas Therapeutics develops bispecific antibody therapies that pair a proprietary proximity engager arm with an antibody against a therapeutic target, using its DualScreen discovery engine to identify synergistic target combinations.
BiotechDeep TechSouth San Francisco, US
Greg Lazar, Ph.D.(Co-Founder and Chief Scientific Officer)Forbes Huang(Co-Founder, Chief Operating Officer & Chief Business Officer)inGreg Lazar(Co-Founder & Chief Scientific Officer)inRichard Murray(Executive Officer, Director)Karim Dabbagh(Chief Executive Officer, Board Member)inKarim Dabbagh, Ph.D.(Chief Executive Officer, Board Member)in
Co-investorsQiming Venture PartnersSV Health InvestorsVersant VenturesDementia Discovery FundQiming HealthcareQiming Venture Partners USA
San Diego protein-sequencing company behind the ProteoCode platform; ceased operations in late 2025.
Co-investorsARCH Venture PartnersDecheng CapitalDeerfield Management CompanyGV (Google Ventures)Nan Fung Life SciencesNorthpond Ventures
Ensoma is a genomic medicine company developing a platform for in vivo engineering of hematopoietic stem cells (HSCs), combining an off-the-shelf delivery system with a gene engineering toolkit intended to treat diseases with a one-time treatment.
BiotechHealthtechMedical DevicesBoston, US
Albert Seymour(Director)
BoardKush Parmar(Executive Officer, Director)inPaula Soteropoulos(Director)Stephen Knight(Director)in
Co-investors5AM VenturesAju IB Invesment CorporationCatalio Capital Management, LPDelos CapitalF-Prime CapitalSolasta Ventures+8 more
EVELO manufactures premium electric bikes designed for comfort and long-distance riding, sold direct-to-consumer with industry-leading warranty and support.
ConsumerDirect to ConsumerE-commerceHardwareMobility & TransportationSeattle, US
Yevgeniy Mordkovich(Executive Officer, Director)inBoris Mordkovich
Co-investorsForefront VentureFlagship PioneeringGV (Google Ventures)Kaiser Permanente Ventures
BiotechCambridge, US
Jennifer Glennon(Executive Officer)inBalkrishan (Simba) Gill, Ph.D.(Executive Officer, Director)Duncan McHale(Executive Officer)inWilliam DeVaul(Executive Officer)inMark Bodmer, Ph.D.(Executive Officer)
BoardNoubar B. Afeyan, Ph.D.(Director)
Co-investorsGV (Google Ventures)SV Health InvestorsFlagship PioneeringKaiser Permanente VenturesMayo Clinic Ventures
Floot is a no-code AI app builder that enables users without coding knowledge to create fully functional mobile and web applications by describing their requirements.
AI & Machine LearningDeveloper ToolsEnterprise SoftwareSaaSSan Francisco, US
Yujian Yao(Founder)inEdward Look(Founder)in
Co-investorsPioneerY Combinator468 CapitalAmino CapitalAndreessen HorowitzBatch Ventures+5 more
-2.png)
Forge Therapeutics operates a drug discovery platform focused on developing medicines that target human metalloenzymes.
BiotechDeep Tech
Co-investorsMC Healthcare Ventures
Fountain is a biotech company developing first-in-class therapies for diseases and conditions caused by aging, using in vitro and in vivo screening platforms to identify drug candidates.
BiotechHealthtechLongevitySan Francisco, US
Thomas Rando(Co-founder)Joseph Rodgers(Co-founder)inTom Cheung(Co-founder)inTsang(Chief Business Officer)
Co-investorsKhosla VenturesNan Fung Life SciencesR42 Group
Genomics company building a multi-ancestry biobank and AI-driven analytics for clinical genetic testing and drug discovery.
HealthtechMiami Lakes, US
Carlos D. Bustamante(Executive Officer, Director)inArthur Polk(Executive Officer)Alexander Ioannidis(Director)
BoardWale Ayeni(Director)inMohit Kaushal(Director)Nicholas Katsanis(Director)
Co-investorsCEI VenturesCitta CapitalF-Prime CapitalFounder CollectiveFunction VenturesHelios Digital Ventures+4 more
Gencove provides direct-to-consumer genetic sequencing and polygenic risk scoring for health insights.
BiotechDigital HealthHealthtechNew York, US
Tomaz Berisa(Executive Officer, Director)inJoseph Pickrell(Executive Officer, Director)in
BoardSara Eshelman(Director)in
Co-investorsBread And Butter Ventures, LlcSpero VenturesVersion One VenturesBalaji SrinivasanBurst CapitalRefactor Capital+1 more
Uses a T-cell antigen discovery platform to develop vaccines for oncology and infectious disease.
BiotechCambridge, US
Narinder Singh(Executive Officer)Derek Meisner(Executive Officer)inMichael Alfieri(Executive Officer)Jessica Flechtner(Executive Officer)Girish Aakalu(Executive Officer)Thomas Davis(Executive Officer)
Co-investorsCycad Group LLCLux CapitalMC Healthcare VenturesAdvent Life SciencesAuriga PartnersBill & Melinda Gates Foundation+1 more
Georgiamune is a biopharmaceutical company developing targeted immunomodulator drugs that activate or down-modulate immune signaling pathways to treat cancer and autoimmune diseases.
BiotechDeep TechHealthtechGaithersburg, US
Samir N. Khleif(Founder & CEO)inRamy Ibrahim(Chief Medical and Strategy Officer)inMikayel Mkrichyan(Senior Vice President of Science and Discovery)Sarah Sharman(Vice President of IP Legal Affairs)
BoardSean Parker(Director)Elena Viboch(Director)in
Co-investorsCatalio Capital Management, LPHAWKTAILLauder PartnersPrevail Venture CapitalCatalio Capital ManagementGeneral Catalyst+3 more
HealthtechCambridge, US
COLIN HILL(Executive Officer, Director)inIYA KHALIL(Executive Officer)inTHOMAS NEYARAPALLY(Executive Officer)MARK POTTLE(Executive Officer)inCAROL MCCALL(Executive Officer)inBRUCE CHURCH(Executive Officer)in
Co-investorsAmgen VenturesEcho Health Ventures
Nexoplex Bio develops immunotherapies that target tumor cells through recognition of HLA-peptide complexes using multi-specific antibodies, addressing tumor types including lung, gastric, esophageal, head and neck, cervical cancers, and lung squamous cell carcinoma.
BiotechDeep TechHealthtechSan Carlos, US
Wayne(CEO)Rachel(VP of Operations)
Co-investorsBay City CapitalGV (Google Ventures)LAVLilly Asia VenturesFrazier Healthcare PartnersThe Column Group+1 more
Holobiome discovers and develops therapies derived from the human gut microbiome, working to translate microbiome science into probiotics and targeted treatments for whole-body health.
AI & Machine LearningBiotechHealthtechLongevityBoston, US
Philip Strandwitz(Co-founder & Director, Chief Executive Officer)inKim Lewis(Co-founder, Director)Mike La Fleur(President, Co-founder, Director)Michael LaFleur(Executive Officer)
BoardJoan LaRovere(Director)inIain Chessell(Director)
Co-investorsAble PartnersAstanor VenturesBantam GroupDeep FutureHealthtech CapitaliSelect Fund+4 more
Clinical-stage genetic medicines company using human-derived AAV vectors and nuclease-free gene editing for rare diseases.
BiotechBedford, US
Siyamak Rasty(Executive Officer)Albert Seymour(Executive Officer)
BoardSteven Gillis(Director)Arthur Tzianabos(Executive Officer, Director)Kush Parmar(Director)inRichard Gregory(Director)
Co-investors5AM VenturesARCH Venture PartnersOUP (Osage University Partners)Deerfield Management CompanyFidelity InvestmentsHBM Healthcare Investments+5 more
Hoofprint Biome develops probiotics and natural enzymes based on microbiome engineering to reduce methane emissions from cattle while improving animal health and feed yield.
AgTechBiotechClimate TechCary, US
Scott Collins(Director)inKathryn Polkoff(Executive Officer, Director)inScott Collins, PhD(Founder)in
BoardRodolphe Barrangou(Director)in
Co-investorsGood Growth CapitalPonderosa VenturesSOSV
IgGenix is a clinical-stage biotechnology company focused on antibody discovery and development for allergies and immunological diseases.
AI & Machine LearningBiotechHealthtechSouth San Francisco, US
Kari Nadeau(Scientific Co-Founder)
Co-investorsKhosla VenturesAllerfund Ventures, LlcFemHealth VenturesGlobal BrainMedical Incubator Japan K.K.ShangBay Capital LLC+1 more
ImCheck Therapeutics develops next-generation immunotherapeutic antibodies targeting the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules for immune system modulation.
BiotechHealthtech
Daniel Olive(Founder)
Co-investorsAgent CapitalAndera PartnersKurma PartnersPfizer Venture InvestmentsPureos BioventuresBpifrance+4 more
Immunai develops AMICA, a data platform for decoding the immune system to accelerate drug discovery and development.
AI & Machine LearningBiotechData & InfrastructureNew York City, US
Co-investorsCatalio Capital Management, LPGefen CapitalKoch Disruptive TechnologiesMeron CapitalPerot JainTLV Partners+2 more
Immusoft develops a cell therapy platform called Immune System Programming (ISP) that engineers a patient's B cells into plasma cells that produce therapeutic proteins after being infused back into the patient.
BiotechDeep TechHealthtechSeattle, US
Matthew Scholz(Founder)inSean Ainsworth(Chief Executive Officer)inRobert Sikorski(Chief Medical Officer)Rob Hayes(Chief Scientific Officer)inScott McIvor(Chief Development Officer)Eric Garcia(Executive Officer)in
Co-investorsBioRock VenturesBoston Harbor AngelsBreakout VenturesEQx FundInvariantes FundMichigan Capital Network+5 more
insitro is a drug discovery and development company that uses machine learning and cellular data to identify therapeutic insights and accelerate the creation of new medicines.
AI & Machine LearningBiotechSouth San Francisco, US
Daphne Koller(Founder & CEO)inDuane Valz(General Counsel)inMary Rozenman(Chief Financial Officer)in
BoardRobert Nelsen(Director)Vijay Pande(Director)in
Co-investorsAndreessen HorowitzARCH Venture PartnersDeviation CapitalForesite CapitalGV (Google Ventures)HOF Capital+9 more
IpiNovyx Bio is a biotech company developing potent and selective immunoproteasome inhibitors to treat cancer, autoimmune, and inflammatory diseases.
BiotechHealthtechMedical DevicesWest Nyack, US
Gang Lin(Scientific Founder)Carl Nathan(Scientific Founder)Franck Barrat(Scientific Founder)inMarc Appel(Executive Officer, Director)Lutz Giebel(Director)James Graham(Director)
Co-investorsPathway Bioventures
Karuna Therapeutics is a Boston neuroscience biopharma behind muscarinic drug KarXT, acquired by Bristol Myers Squibb in 2024.
Co-investorsARCH Venture PartnersPivotal Life SciencesSofinnova VenturesPureTech HealthWellcome Trust
Khartis is a drug discovery company developing oral therapies for patients with immune-mediated and chronic diseases.
BiotechMedical Devices
Co-investorsForesite CapitalNextech InvestLilly Asia VenturesLongwood Fund
Kytopen develops non-viral gene delivery technology called Flowfect that combines fluid flow with electric fields to deliver payloads such as mRNA, DNA, and CRISPR Cas9 RNP into cells for high-throughput transfection.
BiotechDeep TechHardwareCambridge, US
Cullen Buie(Founder; Board Observer)inPaulo Garcia(Founder)inMichael Chiu(Chief Executive Officer)in
BoardPaxton Major(Director)inAnn DeWitt(Director)inPaul Wotton(Director)
Co-investorsBantam GroupHorizons VenturesMassVenturesSelvedge VentureTBD AngelsTelegraph Hill Partners+2 more
LifeMine is a biopharmaceutical company that uses data science and advanced methods to accelerate drug discovery and develop precision medicines across therapeutic areas.
AI & Machine LearningBiotechDeep TechCambridge, US
Gregory L. Verdine(Executive Officer, Director)Gregory Verdine, Ph.D.
BoardHingge Hsu(Executive Officer, Director)Weiqing Zhou(Executive Officer, Director)
Co-investorsARCH Venture PartnersGV (Google Ventures)RA CapitalAisling CapitalBezos ExpeditionsBlue Pool Capital+7 more
Discovering precision small molecule medicines that harness the power of covalency to transform the treatment of immune diseases.
BiotechCambridge, US
Andre Turenne(Executive Officer, Director)in
BoardJason Hafler(Director)inBruce Booth(Director)Daniel Becker(Director)
Co-investorsAccess BiotechnologyDigitalis VenturesSanofi VenturesAccess IndustriesAtlas Venture
The page presents "The Pokies Net," an online casino targeting Australian players with a catalog of over 1,600 pokies, table games, and live dealer titles from providers like NetEnt, Pragmatic Play, and Evolution Gaming.
ConsumerGaming
Co-investorsHAWKTAILNat TurnerRefactor Capital
San Diego clinical-stage biopharma developing non-bile acid FXR agonists for liver and gastrointestinal diseases.
BiotechSan Diego, US
Ronald Evans(Director)Trisha Millican(Executive Officer)Ken Song(Executive Officer, Director)
BoardKristina Burow(Director)inRichard Heyman(Director)inAmir Nashat(Director)in
Co-investorsage1EcoR1 CapitalLAVLifeSci Venture PartnersLilly Asia VenturesNew Enterprise Associates (NEA)+8 more
miRecule is a biotechnology company developing therapeutics, with programs focused on oncology.
BiotechHealthtechGaithersburg, US
Anthony D. Saleh, Ph.D.(CEO)inAnthony D. Saleh(CEO)inDave Lemus(COO/CFO)in
Co-investorsAlumni VenturesBoutique Venture PartnersBrown and White VenturesPathway BioventuresTachyon VenturesUniversity System of Maryland Momentum Fund
Mnemo Therapeutics is a Paris-based clinical-stage biotech developing cell therapies using its EnfiniT epigenetic antigen discovery platform to target tumor-specific antigens for CAR-T therapies.
Co-investorsSofinnova PartnersCasdin CapitalREDMILE
Molecular Assemblies uses a Fully Enzymatic Synthesis (FES) technology to produce long, pure, and accurate synthetic DNA oligonucleotides, up to 400 bases, without post-synthesis purification.
BiotechDeep TechNew MaterialsSan Diego, US
J. William Efcavitch, Ph.D.(Treasurer and Chief Scientific Officer)Michael J. Kamdar(President, Chief Executive Officer and Secretary)
BoardDavid Hwang(Director)Larry Stambaugh(Chairman of the Board of Directors)John Nicols(Director)Todd Peterson(Director)
Co-investors11.2 CapitalDCVC (Data Collective)iSelect FundKeshif VenturesRising TideArgonautic Ventures+2 more
A drug discovery company staffed by scientists and industry specialists focused on developing pharmaceutical candidates.
Biotech
Timur Yusufzai(Founder)inAsit Parikh(Chief Executive Officer)in
Co-investorsLifeSci Venture PartnersNextech InvestThird Rock VenturesCasdin CapitalCreacion VenturesGoldman Sachs+3 more
Mozart Therapeutics develops protein therapeutics focused on immunology and oncology treatments.
BiotechMedical Devices
Mark Davis(Scientific Co-Founder)K. Christopher Garcia(Scientific Co-Founder)Calvin Kuo(Scientific Co-Founder)Katie Fanning(President & Chief Executive Officer)in
Co-investorsARCH Venture PartnersJDRF T1D FundMRL Ventures FundOno Venture Investment, Inc.Pfizer Venture InvestmentsSofinnova Partners+4 more
CREATE Medicines develops in vivo CAR immunotherapy using proprietary mRNA-LNP technology to program T cells, NK cells, and myeloid cells directly within the body for cancer, autoimmunity, and fibrosis.
AI & Machine LearningBiotechHealthtechMedical DevicesCambridge, US
Daniel Getts, Ph.D.(Chief Executive Officer, Cofounder, Board Director)
Co-investorsARCH Venture Partners8VCHatteras Venture PartnersNewpath Partners
nChroma Bio develops in vivo targeted delivery and genetic engineering technologies for genetic medicine applications.
BiotechDeep TechMedical DevicesBoston, US
Luke Gilbert, PhD(Founder)Keith Joung, MD, PhD(Founder)David Liu, PhD(Founder)Angelo Lombardo, PhD(Founder)Luigi Naldini, MD, PhD(Founder)Jonathan Weissman, PhD
Co-investorsAtlas VentureNewpath Partners5AM VenturesARCH Venture PartnersDCVC (Data Collective)F-Prime Capital+11 more
Neurona Therapeutics is a clinical-stage biotherapeutics company developing allogeneic neural cell therapies to treat chronic disorders of the nervous system.
BiotechDeep TechHealthtechSouth San Francisco, US
Cory Nicholas(Executive Officer, Director, Promoter)inJames Stutz(Chief Financial Officer and Chief Business Officer)inCatherine Priest(Chief Development Officer)inGautam Banik(Chief Technology Officer)inEduardo Dunayevich(Chief Medical Officer)inArnold Kriegstein(Director)
Co-investorsBerkeley FrontierIaso VenturesThe Column GroupYsios CapitalFidelity InvestmentsLYFE Capital+7 more
Nilo Therapeutics develops immunomodulation therapies that target brain-body neural circuits controlling systemic inflammation, aiming to treat autoimmune and inflammatory diseases.
BiotechDeep TechHealthtechNew York, US
Jeff Goater(Executive Officer, Director)inKim Seth(CEO)in
BoardTim Kutzkey(Executive Officer, Director, Promoter)in
Co-investorsDCVC (Data Collective)The Column GroupDCVC BioLux Capital
South San Francisco biotech engineering commensal gut bacteria into controllable live therapeutics for chronic diseases.
Daly City, US
Weston Whitaker(Executive Officer, Director, Promoter)William DeLoache(Director)Samuel Smits(Director)
BoardElizabeth Stanley(Director)
Co-investorsAlta PartnersCerity Partners Ventures5AM VenturesDCVC (Data Collective)DCVC BioMayo Clinic Ventures
Nuvig Therapeutics is a biotech company developing immune-modulating therapies for autoimmune and chronic inflammatory diseases, using an endogenous regulatory mechanism intended to treat inflammation without compromising broader immune function.
BiotechLongevity
Co-investorsSanofi Venturesabrdn plcB CapitalDigitalis VenturesGlobal BioAccess FundLeaps by Bayer+4 more
Clinical-stage immuno-oncology company developing antibodies derived from the immune systems of 'Elite' cancer responders.
BiotechHouston, US
Alice Bexon(Executive Officer)inClifford J. Stocks(Director, Executive Officer)inKamal D. Puri(Executive Officer)inChris Russell(Executive Officer)inRuss Hawkinson(Executive Officer)
BoardSteven Gillis(Director)in
Co-investors3B Future Health FundCanaan PartnersGreatPoint VenturesRiverVest Venture PartnersARCH Venture PartnersBering Capital+5 more
A pharmaceutical company developing therapeutics across oncology, hematology, neuroscience, immunology, and cardiovascular disease with a pipeline of 50 compounds targeting 40+ disease areas.
BiotechHealthtechMedical Devices
Co-investorsAndreessen HorowitzARCH Venture PartnersiGlobe PartnersAgent CapitalCasdin CapitalInvus+2 more
Outpace Bio develops engineered protein technologies and cell therapies to treat solid tumors, focusing on protein design and T cell engineering to improve cancer treatment efficacy and safety.
BiotechDeep TechMedical DevicesSeattle, US
Marc Lajoie(Co-founder & Chief Executive Officer)inScott Boyken(Co-founder & Chief Innovation Officer)inStanley Riddell(Co-Founder and Scientific Advisor)Aaron Foster(Executive Officer)inCharity Scripture(Executive Officer)inEric Soller(Executive Officer)in
Co-investorsArtis VenturesRA CapitalAbstract VenturesATEL VenturesAtinum Investment Co. Ltd.Civilization Ventures Management, Llc+8 more
Overt Bio develops cell therapies that link genes to immune functions using genome-scale discovery platforms.
AI & Machine LearningBiotechMedical DevicesNew York, US
Dr. Legut(Co-Founder and CEO)Dr. Sanjana(Co-Founder)Mateusz Legut(Executive Officer, Director)Neville Sanjana(Director)Mat Legut(Founder)in
BoardVasudev Bailey(Director)in
Co-investorsArtis VenturesCivilization Ventures Management, LlcFusionHAWKTAILWingGaingels+1 more
__Twitter.png)
Ozette runs a vertically integrated, AI-enabled lab and platform that generates high-dimensional spectral cytometry data and analyzes it to produce reproducible biomarker endpoints for clinical trials.
AI & Machine LearningBiotechHealthtech
Greg Finak(Founder)inEvan Greene(Co-founder)inAli Ansary(Co-founder)in
Co-investorsAllen Institute for AI (AI2) IncubatorAlpha Ascent Ventures LlcM12 (Microsoft's Venture Fund)Cercano ManagementMadrona Venture GroupOCV Partners
Pheast Therapeutics develops immunotherapies targeting cancer, building on foundational research from Stanford's stem cell research institute.
BiotechHealthtechMedical DevicesRedwood City, US
Irv Weissman(Cofounder, Scientific Advisor, Board Director)Ravi Majeti(Cofounder, Scientific Advisor, Board Observer)Amira Barkal(Principal Founder, Scientific Advisor, Board Director)inRoy Maute(Cofounder & Chief Executive Officer)in
BoardJacob Vogelstein(Director)Steven Gillis(Director)in
Co-investorsARCH Venture PartnersCatalio Capital Management, LPCatalio Capital Management
Precede Biosciences develops a blood-based diagnostic platform that profiles gene expression from cell-free DNA to reveal disease biology at the transcriptional level for drug developers and clinical trials.
AI & Machine LearningBiotechDigital HealthBoston, US
Rehan Verjee(Co-Founder, Chief Executive Officer, Board Director)inSylvan Baca(Co-Founder; Assistant Professor of Medicine, Dana-Farber Cancer Institute)inToni Choueiri(Co-Founder; Director, Lank Center for GU Oncology, Dana-Farber Cancer Institute)Matthew Freedman(Co-Founder; Professor of Medicine, Dana-Farber Cancer Institute)
Co-investors5AM VenturesIllumina VenturesOUP (Osage University Partners)Lilly Asia VenturesOsage University PartnersS28 Capital
Prompt is an Ambient AI product and research company that develops human-centered AI products designed to sense the physical environment.
AI & Machine LearningConsumerDeep TechSan Francisco, US
Tete Xiao(Founder)in
Co-investorsAbstract VenturesAIX VenturesDCVC (Data Collective)Neotribe VenturesBraidwellCDP Venture Capital+4 more
Proniras Corporation is a clinical-stage biotechnology company developing novel small-molecule therapeutics for substance use disorders and specialty central nervous system (CNS) conditions, including treatments for opioid withdrawal and seizure disorders.
BiotechHealthtechSeattle, US
CHRISTOPHER TOOMBS(Executive Officer)inLINDSAY RAYLE(Executive Officer, Promoter)M. Johnston Erwin(Director)David Schubert(Executive Officer, Promoter)
BoardSTEVEN GILLIS(Director)inThong Le(Executive Officer, Director, Promoter)
Co-investorsACCELERATOR LIFE SCIENCE PARTNERSARCH Venture PartnersWRF Capital
Proxima develops AI-powered gaming experiences and infrastructure, with a focus on embodied AI agents and applied AI systems for interactive entertainment.
AI & Machine LearningGamingSan Francisco, US
Ran Mo(Founder)in
Co-investorsKonvoy VenturesProgressionAIX VenturesBalderton CapitalBayern KapitalBraidwell+9 more
Remedy Plan is a biopharmaceutical company developing drugs that target NAMPT, an essential enzyme dysregulated in more than 20 diseases including cancer.
BiotechHealthtechRockville, US
Gregory Plan Crimmins(Executive Officer, Director)
Co-investors20/20 HealthCare Partners LLCSchooner Capital
Boston-based biotech developing drugs against the 'dark genome'/repeatome for autoimmune disease, cancer and neurodegeneration.
Co-investorsAndreessen HorowitzARCH Venture PartnersGV (Google Ventures)Luma GroupSanofi VenturesAbingworth+11 more
Serinus Biosciences uses AI and systems biology to design drug combinations that overcome cancer cells' resistance to existing treatments, targeting safer and more effective therapeutic options.
BiotechHealthtechNew York City, US
Adam Yaari(Founder/CEO)inMaxwell Sherman(Founder/CTO)in
Co-investorsIllumina VenturesMetaplanetPioneerSapir Venture PartnersVertex Ventures IsraelY Combinator+5 more
BiotechDigital HealthMedical DevicesSeattle, US
Peter A. Thompson(Executive Officer, Director)in
Co-investorsEcoR1 CapitalPontifax Venture CapitalRA CapitalUS Venture PartnersNextech InvestOrbiMed
Sonoma provides a governance platform for enterprise deployments of AI agents built on the Model Context Protocol (MCP), offering a self-service MCP catalog, workflow builder, entitlement policies, audit logging, and security controls such as supply chain scanning and prompt injection protection.
AI & Machine LearningCybersecurityEnterprise Software
Stephen Cobbe(Founder)in
Co-investorsFrazier Life SciencesGoAhead VenturesHawk Hill Ventures8VCARCH Venture PartnersLifeforce Capital
SonoThera is developing a nonviral, non-invasive gene delivery technology that uses ultrasound and microbubbles (ultrasound-mediated delivery) to deliver genetic payloads to targeted sites in a redosable way.
BiotechDeep TechDigital HealthHealthtechSouth San Francisco, US
Kenneth Greenberg(Co-Founder, President & CEO)in
Co-investorsVida VenturesLeaps by BayerARCH Venture PartnersFoothill VenturesIllumina VenturesMedical Excellence Capital+8 more
Syros Pharmaceuticals is a Massachusetts gene-control biotech developing small molecules that regulate disease gene expression.
Cambridge, US
Nancy Simonian(CEO)
Co-investorsAisling CapitalARCH Venture PartnersQuan CapitalAlly Bridge GroupBain CapitalBain Capital Life Sciences+11 more
Durham, US
Kris Wood(Director)Eoin McDonnell(Executive Officer, Director)
Co-investorsKdT Ventures
Ten63 develops drug-discovery technology that combines generative chemistry with quantum-accurate molecular simulation, including BEYOND (a large quantum chemistry model) and Sentinel (a virtual CSO for target selection), to design therapeutics against previously undruggable targets.
AI & Machine LearningBiotechDeep TechDurham, US
Mark A. Hallen(Executive Officer, Director)inMarcel Frenkel(Executive Officer, Director)Damien Petty(Director)inJia Wei Xu(Director)
Co-investorsCape Fear BioCapitalDFJ DragonFundDraper AssociatesDuke Capital PartnersHatteras Venture PartnersAbbVie+4 more
PartnerJoel S. Marcus· solo GP
Terray is a drug discovery company that combines proprietary hardware, large-scale experimental datasets, and AI through its EMMI platform to design small molecule medicines.
AI & Machine LearningBiotechDeep Tech
Eli Berlin(Founder)in
BoardChris PicardoinDusan PerovicinSid ShenaiinSamuel BjorkinBassil Dahiyat, Ph.D.
Co-investorsDeviation CapitalDigitalis VenturesMadrona Venture GroupSummit Peak InvestmentsKdT VenturesMana Ventures+5 more
BiotechCambridge, US
James G. McArthur(Executive Officer)Abraham N. Ceesay(Executive Officer)Christoph M. Adams(Executive Officer, Director)
BoardMette Kirstine Agger(Director)David Mott(Director)Sandip Agarwala(Director)
Co-investorsLongitude CapitalLundbeckfonden VenturesNew Enterprise Associates (NEA)
Transforming the food system using seaweed, a highly sustainable protein source.
Albany, US
Beth Zotter(Executive Officer, Director)inAmanda Stiles(Director)in
Co-investorsClear Current CapitalCollaborative FundISVJuniperSustainable Food VenturesAgFunder+2 more
.jpeg){kind=logo}
Valora Therapeutics is a biotech company developing antibody-lectin chimera (AbLec) therapeutics that target cell-surface glycans for immuno-oncology and immunotherapy applications.
BiotechHealthtechLa Jolla, US
Miguel Garcia-Guzman(Co-Founder, CEO & Director)inCarolyn Bertozzi(Scientific Co-Founder)Jessica Stark(Scientific Co-Founder)inJames Lee(VP, Business Development)in
BoardStefan Heller(Director)Sanford Madigan(Director)in
Co-investorsAvalon BioVenturesCorrelation Ventures
Ventus AI is an enterprise automation platform offering AI agents ("AI teammates") that operate inside existing systems—desktop apps, web portals, and legacy software—without API integrations to automate complex business workflows, handling MFA, CAPTCHAs, and phone calls.
AI & Machine LearningEnterprise SoftwareHealthtechCasa Grande
Maran Vedamanikam(CEO and Manager)
Co-investorsSamsung NextAndreessen HorowitzWndrCoBiotechnology Value FundCasdin CapitalFonds de solidarité FTQ+5 more
Developing novel treatments based on the 12-LOX pathway for immuno-inflammatory diseases.
Co-investorsAlumni VenturesHatteras Venture PartnersPappas CapitalSanofi VenturesGenesys CapitalJDRF T1D Fund+4 more
Vividion Therapeutics develops small molecule therapeutics using a covalent-first chemoproteomics approach to identify and target previously undruggable proteins.
AI & Machine LearningBiotechDeep TechPrinceton, US
Ben Cravatt(Scientific Founder)Phil Baran(Scientific Founder)Jin-Quan Yu(Scientific Founder)Aleksandra Rizo(President and Chief Executive Officer)in
BoardJohn Park(Executive Officer)John Clarke(Executive Officer, Director)in
Co-investorsARCH Venture PartnersAvoro Capital AdvisorsCardinal PartnersNextech InvestSoftBank Vision FundALTITUDE LIFE SCIENCE VENTURES+4 more
ZymoChem develops bio-based materials using proprietary Carbon Conserving (C2) microbes that convert renewable feedstocks into high-value materials with increased yields.
BiotechCircular EconomyClimate TechNew MaterialsSan Leandro, US
Harshal Chokhawala(Founder & CEO)in
Co-investorsAccelr8Breakout LabsBreakout VenturesCavallo VenturesDudley FundFreshTracks Capital+7 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Frequency TherapeuticsAtommapBoragenCalimmuneCydan IIEpiBiomeGenePeeksLodo TherapeuticsMagnolia NeurosciencesNohla TherapeuticsOzette Technologies, Inc.Petra PharmaPrevail TherapeuticsQuentisRodeo TherapeuticsShenandoah GrowersTARA BiosystemsX-Vax TechnologyXilis, Inc.Yumanity Therapeutics
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 21
11 IPOs · 10 acquisitions · showing 14Boundless BioNASDAQ: BOLDDisc MedicineNASDAQ: IRONImaraNASDAQ: ELVNKorro BioNASDAQ: KRROMaze TherapeuticsNASDAQ: MAZENeumora TherapeuticsNASDAQ: NMRASenti BiosciencesNASDAQ: SNTIBear Flag Roboticsacq. by John DeereCalimmuneacq. by CSL BehringCelsius Therapeuticsacq. by AbbVieImcheckacq. by ClementiaSilverback Therapeuticsacq. by ARS PharmaceuticalsVeraloxacq. by Cadrenal TherapeuticsVividion Therapeuticsacq. by Bayer
Portfolio news
latest coverage across their companies
LifeMine Therapeutics · finsmes.com · Aug 8, 2026
SonoThera · finsmes.com · Jun 10, 2026
Kytopen · finsmes.com · Apr 7, 2026
Immusoft · immusoft.com · Mar 30, 2026
Dren Bio · biospace.com · Mar 2, 2026
IPO stake values · per SEC filings
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Korro Bio | — | $14.00 | Oct 2019 | $13.4M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- How many investments has Alexandria made?
- Alexandria has 116 tracked investments, 21 of which have exited, including 15 dated in the last 24 months.
- What stage does Alexandria invest at?
- Alexandria invests at the Seed, Series A, Series B, Late Stage stages.
- What sectors does Alexandria focus on?
- Alexandria focuses on AgTech, AI & Machine Learning, Biotech, Healthtech, Medical Devices.
- Where is Alexandria located?
- Alexandria is headquartered in Pasadena, US.
Similar investors
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests in technology companies from seed to growth stage. Since inception it has backed over 200 companies and raised more than $1.3 billion.
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Corner Ventures is a venture capital firm that invests in technology companies at key development stages.